Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$0.43 - $0.79 $8,373 - $15,384
-19,474 Reduced 90.32%
2,087 $1,000
Q3 2023

Nov 13, 2023

SELL
$0.73 - $1.04 $57,369 - $81,732
-78,589 Reduced 78.47%
21,561 $16,000
Q2 2023

Aug 14, 2023

BUY
$0.9 - $1.51 $47,093 - $79,012
52,326 Added 109.41%
100,150 $92,000
Q1 2023

May 15, 2023

BUY
$1.06 - $2.16 $22,072 - $44,977
20,823 Added 77.12%
47,824 $52,000
Q4 2022

Feb 14, 2023

BUY
$1.05 - $2.53 $28,351 - $68,312
27,001 New
27,001 $39,000
Q2 2022

Aug 15, 2022

BUY
$1.33 - $2.28 $58,474 - $100,242
43,966 New
43,966 $75,000
Q2 2020

Aug 14, 2020

SELL
$2.58 - $12.1 $31,390 - $147,220
-12,167 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$1.2 - $4.52 $14,600 - $54,994
12,167 New
12,167 $33,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $121M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.